- Soligenix, Inc. announced the closing of a public offering on **September 29, 2025**, generating approximately **$7.5 million** in gross proceeds.  **[812796_0001104659-25-094507_sngx-20250925xex99d2.htm:0]** **[812796_0001104659-25-094507_sngx-20250925x8k.htm:1]** 
- The offering involved the sale of **5,555,560 shares** of common stock (or common stock equivalents) and warrants to purchase up to **5,555,560 shares** of common stock, at a combined purchase price of **$1.35 per share** and accompanying warrant.  **[812796_0001104659-25-094507_sngx-20250925xex99d2.htm:0]** **[812796_0001104659-25-094507_sngx-20250925xex99d1.htm:0]** 
- This funding is expected to extend the company's cash runway through the **end of 2026** and will be used for research and development, commercialization activities, working capital, and general corporate purposes.  **[812796_0001104659-25-094507_sngx-20250925xex99d2.htm:0]** **[812796_0001104659-25-094507_sngx-20250925x8k.htm:1]** 
- Additionally, certain existing warrants to purchase **1,162,064 shares** were amended to have a reduced exercise price of **$1.35 per share** and will expire commensurate with the warrants sold in the offering.  **[812796_0001104659-25-094507_sngx-20250925xex99d2.htm:0]** **[812796_0001104659-25-094507_sngx-20250925x8k.htm:1]**

Soligenix Announces Closing of Public Offering

- Soligenix, Inc. has closed a public offering, generating approximately **$7.5 million** in aggregate gross proceeds.  **[812796_20250929CG86112:0]** 
- The offering involved the sale of **5,555,560 shares of common stock** (or equivalents) and warrants to purchase up to **5,555,560 shares of common stock** at a combined purchase price of **$1.35 per share** and accompanying warrant.  **[812796_20250929CG86112:0]** 
- This funding is expected to extend the Company's cash runway through the **end of 2026**.  **[812796_20250929CG86112:0]** 
- Proceeds from the offering are intended to fund research and development, commercialization activities, working capital, and general corporate purposes.  **[812796_20250929CG86112:0]**

- Soligenix, Inc. (SNGX) announced the pricing of a "reasonable best efforts" public offering with existing and certain healthcare focused institutional investors.  **[812796_20250926PH84064:0]** 
- The offering includes **5,555,560 shares of common stock** (or equivalents) and warrants to purchase up to **5,555,560 shares of common stock** at a combined purchase price of **$1.35 per share and accompanying warrant**.  **[812796_20250926PH84064:0]** 
- The gross proceeds from the offering are expected to be approximately **$7.5 million**, with net proceeds intended to fund research and development, commercialization activities, working capital, and general corporate purposes.  **[812796_20250926PH84064:0]** 
- The company also agreed to amend certain existing warrants for **1,162,064 shares** to reduce their exercise price to **$1.35 per share**.  **[812796_20250926PH84064:0]** 
- The closing of the offering is expected to occur on or about **September 29, 2025**.  **[812796_20250926PH84064:0]**

Soligenix Prices Public Offering

- **Soligenix, Inc.** (Nasdaq: SNGX) announced the appointment of **Tomas J. Philipson, PhD** as a Strategic Advisor on **September 23, 2025**.  **[812796_20250923PH80340:0]** 
- Dr. Philipson, an expert in U.S. economic and healthcare policy, previously served as **vice chairman and acting chairman of President Trump's White House Council of Economic Advisers** from 2017 to 2020.  **[812796_20250923PH80340:0]** 
- He will support Soligenix in advancing its lead product candidate **HyBryte™**, currently in a confirmatory Phase 3 clinical trial, and other rare disease pipeline programs towards marketing approval and commercialization.  **[812796_20250923PH80340:0]** 
- HyBryte™ is a novel photodynamic therapy for **cutaneous T-cell lymphoma (CTCL)**, a rare form of non-Hodgkin's lymphoma, and has received orphan drug and fast track designations from the FDA, as well as orphan designation from the European Medicines Agency (EMA).  **[812796_20250923PH80340:1]** **[812796_20250923PH80340:4]** 
- A second, confirmatory Phase 3 study, **FLASH2**, is expected to be initiated before the end of 2024 to support marketing approval, with agreement from the EMA on key design components.  **[812796_20250923PH80340:3]**

SOLIGENIX (SNGX)